...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials
【24h】

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

机译：人类先前存在的5型，6型，26型和36型中和抗体的腺病毒的国际流行病学：高Ad5滴度的相关性及其对潜在HIV疫苗试验的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Replication-defective adenoviruses have been utilized as candidate HIV vaccine vectors Few studies have described the international epidemiology of pre-existing immunity to adenoviruses We enrolled 1904 participants in a cross-sectional serological survey at seven sites in Africa, Brazil, and Thailand to assess neutralizing antibodies (NA) for adenovirus types Ad5, Ad6, Ad26 and Ad36 Clinical trial samples were used to assess NA titers from the US and Europe The proportions of participants that were negative were 14 8%(Ad5), 31 5%(Ad6),41 2%(Ad26) and 53.6% (Ad36) Adenovirus NA titers varied by geographic location and were higher in non-US and non-European settings, especially Thailand In multivariate logistic regression analysis, geographic setting (non-US and non-European settings) was statistically significantly associated with having higher Ad5 titers, participants from Thailand had the highest odds of having high Ad5 titers (adjusted OR = 3 53,95% CI 224,557) Regardless of location. titers of Ad5NA were the highest and Ad36 NA were the lowest Coincident Ad5/6 titers were lower than either Ad5 or Ad6 titers alone Understanding pre-existing immunity to candidate vaccine vectors may contribute to the evaluation of vaccines in international populations
机译：复制缺陷型腺病毒已被用作候选HIV疫苗载体很少有研究描述了对腺病毒已有免疫力的国际流行病学。我们在非洲，巴西和泰国的7个地点对1904名参与者进行了横断面血清学调查，以评估中和作用使用Ad5，Ad6，Ad26和Ad36型腺病毒的抗体（NA），通过临床试验样品评估来自美国和欧洲的NA滴度。阴性受试者的比例为14 8％（Ad5），31 5％（Ad6）， 41 2％（Ad26）和53.6％（Ad36）腺病毒NA效价因地理位置而异，在非美国和非欧洲地区（尤其是泰国）中较高，在多因素Logistic回归分析中，地理环境（非美国和非欧洲地区）设置）在统计学上与较高的Ad5效价显着相关，来自泰国的参与者具有较高的Ad5效价的几率最高（调整后的OR = 3 53,95％CI 224,557），无论地点如何。 Ad5NA滴度最高，Ad36 NA最低，同时发生Ad5 / 6滴度低于单独的Ad5或Ad6滴度。了解对候选疫苗载体的既存免疫力可能有助于评估国际人群中的疫苗

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号